PBS Biotech, based in Camarillo, Calif., designs single-use bioreactor systems that use proprietary Vertical-Wheel® technology to create homogeneous, scalable mixing for sensitive cell culture and cell therapy applications. The company also offers process development services to support customers advancing cell- and gene-based therapies. PBS says it aims to become the world’s standard manufacturing platform for allogeneic cell-based therapies and is investing in new product innovation and applications development. PBS recently secured follow-on growth capital to accelerate product innovation, process development, and quality-system improvements. The company is expanding ISO 9001:2015 manufacturing capacity, targeting completion by mid-2025 and readiness to support more than $100 million in annual revenue. Leadership additions include a new Chief Commercial Officer and Chief Financial Officer to support commercial expansion and scaling efforts. PBS Biotech is a Camarillo, CA-based manufacturer of single-use bioreactor systems and a provider of process development services. Its bioreactors employ proprietary Vertical-Wheel technology to deliver homogeneous, scalable mixing for sensitive cell therapy products and other cell culture applications. The company is led by CEO Brian Lee and serves global cell therapy clients. PBS Biotech raised $22M in funding to support its growth. It intends to use the proceeds to improve its product portfolio, expand its process development services capability, and increase customer support for global cell therapy customers. The financing accompanies a board appointment from the lead investor. PBS Biotech manufactures single-use bioreactor systems built around its proprietary Vertical-WheelTM technology, designed for shear-sensitive cell therapy products. Its systems provide unique mixing properties and environmental conditions that studies have shown to outperform traditional stirred-tank bioreactors. The company operates an in-house bioprocess R&D facility and offers contract process development services to help customers scale from research to clinical and commercial production. PBS’s systems are used by over 200 customers and are particularly suited for iPSC, MSC, and exosome-based therapy manufacturing. PBS recently closed a private $10M financing to expand and industrialize its product portfolio and develop GMP-qualified bioreactor systems. The company plans to expand its product line over the next several years to support customers through clinical trials to commercialization and pursue a leading position in allogeneic cell therapy manufacturing.

Total raised

$49M

Funding rounds

3

Latest round

Equity

Latest activity

Jan 2025